Med device ID compliance deadlines coming down the pike; Domain Surgical raises $11.6M to advance surgical device;

@FierceMedDev: Lombard Medical in the U.K. detailed plans for a proposed $80M IPO driven by its aortic repair device. S-1 form | Follow @FierceMedDev

@MarkHFierce: Exosome Diagnostics raised $27M to bring its prostate cancer urine test to market. More | Follow @MarkHFierce

@MichaelGFierce: Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Industry report shows bleak 2013 for med tech industry. Story | Follow @EmilyWFierce

@GalenMoore: Spanish researchers find a protein adults need for brain plasticity could delay the effects of Alzheimer's disease. Abstract | Follow @GalenMoore

> Medical device manufacturers face a looming deadline to start complying with the FDA's Unique Device Identification System, but some of the practical implications remain unresolved. Story

> Utah's Domain Surgical has raised $11.6 million to help back the advance of its device that enables soft tissue cutting and coagulation. Story

> The chairman of AngioDynamics ($ANGO) has retired, and the medical device manufacturer said his departure "is not the result of any disagreement." Story

> MedShape gained 510(k) clearance for its Morphix SP Suture Anchor. Story

> Minnesota's Sterilucent gained a CE mark for its hydrogen peroxide sterilizer and sterilant, a product recently exhibited at a major trade show in Germany, Story

Biotech News

@FierceBiotech: Kythera buys back Bayer's stake in PhIII chin-fat therapy in $84M deal. News | Follow @FierceBiotech

@JohnCFierce: Commentary--The dying child vs. the biotech: Everybody loses. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Yesteryear's megamergers are, in part, driving Big Pharma's external R&D push, says John LaMattina. Forbes piece | Follow @DamianFierce

@EmilyMFierce: Scientists from Notre Dame ID new class of antibiotics to combat MRSA. Story | Follow @EmilyMFierce

> Lumena banks $45M and hits the gas on two liver treatments. More

> Novartis's new Basel campus reflects Vasella's (now out-of-fashion) style. Article

Pharma News

@FiercePharma: Yesterday's top-read news: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma

@TracyStaton: Every Dog Has Its Data: The quantified self for pets, via The New York Times. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: Pfizer's Effexor XR one of a host of recalls lately that include products from Mylan, Baxter and Gilead. More | Follow @EricPFierce

@CarlyHFierce: As promised: BTG recoils at rattlesnake roundup 'gassing.' Item | Follow @CarlyHFierce

> Bayer's Nexavar falls short in new liver cancer trial. Story

> Pharma wins battle against proposed Medicare reimbursement changes. More

Biotech Research News

> University of Notre Dame team IDs new class of antibiotics. Article

> Stem cell therapy improves Parkinson's symptoms in monkeys. Story

> NIH faces flat funds in president's 2015 budget proposal. News

> Seattle BioMed receives $10M NIAID grant to lead AIDS vaccine effort. News

> Antipsychotic drugs may have another use: Treating deadly brain tumors. Story

> OHSU opens new stem cell research center. Brief

Pharma Manufacturing News

> BMS joins Merck with plans to whack plants in Ireland. News

> Global rise in pain drug use puts the hurt on Tasmania's poppy production. Story

> Source: Ranbaxy shops for Nexium API to salvage lucrative launch. Article

> Ranbaxy recalls generic Lipitor after druggist finds 20-mg dose in 10-mg bottle. News

> Pfizer recalls bottles of antidepressant that might have a heart drug mixed in. Story

> Pfizer is expanding its plant in Indonesia--again. Brief

 

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.